Table 1.
Characteristics and treatment factors of patients.
| Variables | Strata | IG-IMRT | HDR-BT | p-Value | |||
|---|---|---|---|---|---|---|---|
| n = 270 | n = 353 | ||||||
| No. or Median (range) | (%) | No. or Median (range) | (%) | ||||
| Age | 71 (47–86) | 71 (51–86) | 0.001 | ||||
| T category | 1 | 87 | (32%) | 95 | (27%) | 0.057 | |
| 2 | 118 | (44%) | 155 | (44%) | |||
| 3 | 64 | (24%) | 94 | (27%) | |||
| 4 | 1 | (0.4%) | 9 | (3%) | |||
| Pretreatment PSA | ng/mL | 11.82 (1.971–658) | 9.7 (4–265) | 0.002 | |||
| Gleason score | ≤6 | 86 | (32%) | 117 | (33%) | 0.0002 | |
| 7 | 77 | (29%) | 147 | (42%) | |||
| 8≤ | 107 | (40%) | 89 | (25%) | |||
| NCCN risk classification | Low | 48 | (18%) | 28 | (8%) | <0.0001 | |
| Intermediate | 75 | (28%) | 145 | (41%) | |||
| High | 128 | (47%) | 141 | (40%) | |||
| Very high | 19 | (7%) | 39 | (11%) | |||
| Prescribed dose | 74.8 Gy | 102 | (38%) | 45.5 Gy | 86 | (24%) | NA |
| 72.6 Gy | 24 | (9%) | 49 Gy | 148 | (42%) | ||
| 74 Gy | 119 | (44%) | 54 Gy | 111 | (31%) | ||
| 72 Gy | 25 | (9%) | Others | 8 | (2%) | ||
| 74.8 Gy | 102 | (38%) | |||||
| Hormonal therapy | Yes | 176 | (65%) | 275 | (78%) | 0.0005 | |
| No | 94 | (35%) | 78 | (22%) | |||
| Follow-up | Months | 74 (24–97) | 84 (19–216) | 0.001 | |||
Bold values indicate statistical significance. HDR-BT: high-dose-rate brachytherapy. IG-IMRT: image-guided intensity-modulated radiotherapy. NCCN: National Comprehensive Cancer Network. PSA: prostate-specific antigen.